Why do we need another interferon?

Gastroenterology

Volumn 139, Issue 4, 2010, Pages 1084-1086

  Pockros, Paul J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIFN; ALBINTERFERON ALPHA2B; IFN ALPHA 2B XL; INFERGEN XL; JOULFERON; LAMBDA IFN; LOCTERON; OMEGA IFN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; ZALBIN; ALBUMINOID; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADVERSE OUTCOME; ALOPECIA; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; THORAX RADIOGRAPHY; WEIGHT REDUCTION; CLASSIFICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ALBUMINS; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 77957367132     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.08.015     Document Type: Editorial

References (17)

1. P.J. Pockros New direct acting antivirals (DAAs) in development for HCV infection Ther Adv Gastroenterol 3 2010 191 202
2. J.M. Pawlotsky, S. Chevaliez, and J.G. McHutchison The hepatitis C virus life cycle as a target for new antiviral therapies Gastroenterology 132 2007 1979 1998
3. C. Hezode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
4. B.R. Bacon, M.L. Shiffman, and F. Mendes Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results Hepatology 49 2009 1838 1846
5. G.M. Subramanian, M. Fiscella, and A. Lamous-Smith Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nature Biotech 25 2007 1411 1419
6. V.G. Bain, K.D. Kaita, and E.M. Yoshida A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients J Hepatol 44 2006 671 678
7. S. Zeuzem, E.M. Yoshida, and Y. Benhamou Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C Hepatology 48 2008 407 417
8. D.R. Nelson, Y. Benhamou, and W.-L. Chuang Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis c virus genotype 2 or 3 Gastroenterology 139 2010 1267 1275
9. S. Zeuzem, M.S. Sulkowski, and E.J. Lawitz Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis c virus genotype 1 Gastroenterology 139 2010 1257 1266
10. Human Genome Sciences announces preliminary feedback from FDA on Zalbin BLA for chronic hepatitis C [press release] June 14, 2010 Human Genome Sciences, Inc Rockville, MD
11. Human Genome Sciences announces withdrawal of European Marketing Authorization Application for Jouferon® Zalbin™ for the treatment of chronic hepatitis C [press release] April 19, 2010 Human Genome Sciences, Inc Rockville, MD
12. D.R. Nelson Safety and efficacy of albinterferon-alfa-2b every four weeks plus ribavirin for treatment of chronic hepatitis C genotype 2/3 Hepatology 2010 [abstract]
13. A.J. Thompson, A.J. Muir, and M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 128
14. V. Novozhenov, N. Zakharova, and E. Vinogradova Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype 1 infection J Hepatol 46 2007 S8
15. C. Trepo, M. Guest, and R. Meyrueix Evaluation of antiviral activity and tolerance of a novel sustained release interferon-alpha-2B (IFN-ALPHA-2BXL) compared to pegylated interferon-alpha-2B (PEG-IFN-ALPHA-2B): a phase 1B trial in HCV patients J Hepatol 48 Suppl 2 2008 S28
16. L.G. De Leede, J.E. Humphries, and A.C. Bechet Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial J Interferon Cytokine Res 28 2008 113 122
17. T. Marcello, A. Grakoui, and G. Barba-Spaeth Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898